The stock appears overpriced with its high beta causing amplified price movements. Its optimistic future growth seems already factored into the current share price, making it potentially not the best time to buy as it has outpaced its industry peers.
Despite lower forecasted growth, Life Time Group's P/S ratio is on par with industry peers, hinting investor loyalty. However, alignment of P/S ratio with the growth outlook could result in disappointment. Weak revenue outlook puts the share price at risk requiring positive change to justify P/S ratio.
Life Time股票讨论区
资产负债表上商誉及其他无形资产14.1亿,占净资产21.24亿的2/3。长期借款18.1亿,占净资产的85%,杠杆率不算低。
资产的流动性很差,66.3亿总资产中仅有1.3亿流动资产,目前流动比率降到了0.3,风险非常大,目前缺乏投资价值。
专栏Today's Pre-Market Stock Movers: BMY, ADBE, MSTR, AZN and More
Select biotech/pharma names showing strength following ESMO:
$Clovis Oncology(CLVS.US)$ +11.3%, $Cardiff Oncology(CRDF.US)$ +9%, $Immatics(IMTX.US)$ +8.3%, $IDEAYA生物科学(IDYA.US)$ +8%, $Lyra Therapeutics(LYRA.US)$ +5.7%, $POINT Biopharma(PNT.US)$ +5.7%, $Edgewise Therapeutics(EWTX.US)$ +4.7%, $Concert Pharmaceuticals(CNCE.US)$ +3.6%, $Deciphera Pharmaceuticals(DCPH.US)$ +3.2%, $Veracyte(VCYT.US)$ +2.6%, $SpringWorks Therapeutics(SWTX.US)$ +2.3%,...
暂无评论